Levasseur L - Search Results

1

SARS-CoV-2 seroprevalence in the adult detainees of the Paris area in 2021: A multicenter cross-sectional study.

Mellon G, Rouquette A, Fac C, Carton B, Cordonnier F, David E, Goutte B, Heulin F, Kanoui V, Levasseur L, Racle P, Silberman B, Nehri K, Dulioust A, Roque-Afonso AM. Mellon G, et al. Among authors: levasseur l. J Infect. 2022 Aug;85(2):e40-e43. doi: 10.1016/j.jinf.2022.05.032. Epub 2022 Jun 2. J Infect. 2022. PMID: 35659551 Free PMC article. No abstract available.

2

Effects of mode of inhalation of carbon monoxide and of normobaric oxygen administration on carbon monoxide elimination from the blood.

Levasseur L, Galliot-Guilley M, Richter F, Scherrmann JM, Baud FJ. Levasseur L, et al. Hum Exp Toxicol. 1996 Nov;15(11):898-903. doi: 10.1177/096032719601501106. Hum Exp Toxicol. 1996. PMID: 8938485

3

Fast automated analysis of strong gravitational lenses with convolutional neural networks.

Hezaveh YD, Levasseur LP, Marshall PJ. Hezaveh YD, et al. Among authors: levasseur lp. Nature. 2017 Aug 30;548(7669):555-557. doi: 10.1038/nature23463. Nature. 2017. PMID: 28858317

4

Optimal design for estimating parameters of the 4-parameter hill model.

Khinkis LA, Levasseur L, Faessel H, Greco WR. Khinkis LA, et al. Among authors: levasseur l. Nonlinearity Biol Toxicol Med. 2003 Jul;1(3):363-77. doi: 10.1080/15401420390249925. Nonlinearity Biol Toxicol Med. 2003. PMID: 19330140 Free PMC article.

5

[Frequency of re-incarcerations in the same detention center: role of substitution therapy. A preliminary retrospective analysis].

Levasseur L, Marzo JN, Ross N, Blatier C. Levasseur L, et al. Ann Med Interne (Paris). 2002 May;153(3 Suppl):1S14-9. Ann Med Interne (Paris). 2002. PMID: 12218878 French.

6

Effect of alosetron on the pharmacokinetics of alprazolam.

D'Souza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM. D'Souza DL, et al. Among authors: levasseur lm. J Clin Pharmacol. 2001 Apr;41(4):452-4. doi: 10.1177/00912700122010168. J Clin Pharmacol. 2001. PMID: 11304902 Clinical Trial.

7

Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats.

Delon A, Levasseur LM, Giraudon M, Bouquet S, Couet W. Delon A, et al. Among authors: levasseur lm. Pharm Res. 1999 Dec;16(12):1894-7. doi: 10.1023/a:1011967813140. Pharm Res. 1999. PMID: 10644081 No abstract available.

8

Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay.

Levasseur LM, Faessel H, Slocum HK, Greco WR. Levasseur LM, et al. J Pharmacokinet Biopharm. 1998 Dec;26(6):717-33. doi: 10.1023/a:1020755124451. J Pharmacokinet Biopharm. 1998. PMID: 10485082

9

Parabolic growth patterns in 96-well plate cell growth experiments.

Faessel HM, Levasseur LM, Slocum HK, Greco WR. Faessel HM, et al. Among authors: levasseur lm. In Vitro Cell Dev Biol Anim. 1999 May;35(5):270-8. doi: 10.1007/s11626-999-0071-z. In Vitro Cell Dev Biol Anim. 1999. PMID: 10475273

10

Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.

Levasseur LM, Slocum HK, Rustum YM, Greco WR. Levasseur LM, et al. Cancer Res. 1998 Dec 15;58(24):5749-61. Cancer Res. 1998. PMID: 9865733

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page